Literature DB >> 24030171

Surgical outcomes and predictors of stroke in a North American white and African American moyamoya population.

Grant W Mallory1, Regina S Bower, Macaulay E Nwojo, Philipp Taussky, Nicholas M Wetjen, Thais C Varzoni, Ricardo A Hanel, Fredric B Meyer.   

Abstract

BACKGROUND: The majority of moyamoya surgical series have been confined to Asian and pediatric populations. Few have studied demographics, risk factors, and outcomes in adult North American populations.
OBJECTIVE: To examine outcomes after revascularization for moyamoya in white and African American adults and to assess for predictors of recurrent stroke.
METHODS: A retrospective review of 75 non-Asian patients undergoing 110 procedures at the Mayo Clinic was performed. Demographics, known moyamoya associations, cerebrovascular risk factors, and autoimmune diseases were recorded. Primary outcomes for vascular events were assessed with Kaplan-Meier analysis. Fisher exact methods were used to evaluate for associations with recurrent events.
RESULTS: Mean age was 42 years, and mean follow-up was 47 months. Seventy-one of the 75 patients were white. The majority had bilateral disease (n = 49). Perioperative ischemic events occurred in 5 patients (4.5%). The 5- and 10-year event rates were 5.8% and 9.9%. Significant associations were found with a history of thyroid disease (P = .05) and recurrent stroke. A trend was also found between hypertension and autoimmune disease with recurrent stroke.
CONCLUSION: Outcomes were favorable with revascularization in this subset with moyamoya. A significant association between a history of thyroid disease and recurrent stroke was found. Additionally, high prevalences of autoimmune disease, hypertension, and thyroid disease were found in our cohort, suggesting that they may play a role in the pathophysiology and progression of moyamoya disease in this population. A new classification for moyamoya is proposed based on these data.

Entities:  

Mesh:

Year:  2013        PMID: 24030171     DOI: 10.1227/NEU.0000000000000162

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Clinical Use of Cerebrovascular Compliance Imaging to Evaluate Revascularization in Patients With Moyamoya.

Authors:  Jennifer M Watchmaker; Blaise deB Frederick; Matthew R Fusco; Larry T Davis; Meher R Juttukonda; Sarah K Lants; Howard S Kirshner; Manus J Donahue
Journal:  Neurosurgery       Date:  2019-01-01       Impact factor: 4.654

2.  Patients with Moyamoya Vasculopathy Evaluated at a Single-Center in The Netherlands; Clinical Presentation and Outcome.

Authors:  Annick Kronenburg; Rachel Kleinloog; Albert van der Zwan; L Jaap Kappelle; Luca Regli; Kees P J Braun; Catharina J M Klijn
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

Review 3.  Diagnosis of moyamoya disease: international standard and regional differences.

Authors:  Miki Fujimura; Teiji Tominaga
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

4.  Identification of HLA-DRB1*04:10 allele as risk allele for Japanese moyamoya disease and its association with autoimmune thyroid disease: A case-control study.

Authors:  Ryosuke Tashiro; Kuniyasu Niizuma; Seik-Soon Khor; Katsushi Tokunaga; Miki Fujimura; Hiroyuki Sakata; Hidenori Endo; Hidetoshi Inoko; Koetsu Ogasawara; Teiji Tominaga
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

Review 5.  Characteristics of Moyamoya Disease in the Older Population: Is It Possible to Define a Typical Presentation and Optimal Therapeutical Management?

Authors:  Ignazio G Vetrano; Anna Bersano; Isabella Canavero; Francesco Restelli; Gabriella Raccuia; Elisa F Ciceri; Giuseppe Faragò; Andrea Gioppo; Morgan Broggi; Marco Schiariti; Laura Gatti; Paolo Ferroli; Francesco Acerbi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

Review 6.  Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome.

Authors:  Pietro Fiaschi; Marcello Scala; Gianluca Piatelli; Domenico Tortora; Francesca Secci; Armando Cama; Marco Pavanello
Journal:  Neurosurg Rev       Date:  2020-09-21       Impact factor: 3.042

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.